Skip to main content

We’re happy to announce Newswire has acquired HeadTalker!

From the beginning of HeadTalker, we have always placed the comments and happiness of our community first and we believe with this acquisition, we’ll continue to build out our vision for social media virality for brand campaigns as well as improving the opportunities to our user base.

Newswire and HeadTalker are committed to create new and better ways to take a social media message viral.

For now, HeadTalker with continue to function as it does today. Your Headtalker account and campaigns will continue as normal and we’ll be providing more details on upcoming plans for Headtalker in the coming weeks.

If you have any questions, please contact us.

Team HeadTalker and Newswire


By OncoGambit

Created 1 | Supported 0

29 of 100



Social Reach


Ended 01/07/2023

"Optimal cancer treatment at your fingertips"

— OncoGambit and
other supporters

Share | How It Works | Embed

  OncoGambit was designed to meet the need of cancer patients to validate their treatments recommendations from their doctors. It is a software designed to aggregate all national guidelines which are based on the latest research and the consensus of over 1100 cancer experts. With OncoGambit all patients can confirm or validate that the treatment recommended by their oncologist is the most up-to-date, research-based that ensures the best survival. Our mission is to serve as a global community for cancer patients to gain peace of mind prior to treatment by validating their treatment, while educating them about their own cancer and how the treatment is derived.

No Campaign Updates. Check Back Sometime Soon.

Created on 2022-12-13 14:53:07